An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side
Frontiers in Neuroscience, 2021 There is a substantial need for new pharmacological treatments of addiction, and appetite-regulatory peptides are implied as possible candidates. Appetite regulation is complex and involves anorexigenic hormones such as glucagon-like peptide-1 (GLP-1 ...
Olesya T. Shevchouk +2 more
doaj +1 more source
The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach [PDF]
, 2013 The calcitonin gene-related peptide (CGRP) receptor is a complex of a calcitonin receptor-like receptor (CLR), which is a family B G-protein-coupled receptor (GPCR) and receptor activity modifying protein 1.
Alex C. Conner +13 more
core +2 more sources
A novel Dual Amylin and Calcitonin Receptor Agonist (DACRA), KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference [PDF]
, 2017 BACKGROUND AND PURPOSE: Obesity and associated co‐morbidities, such as type 2 diabetes and non‐alcoholic fatty liver disease, are major health challenges.
Aballay +48 more
core +1 more source
JCEM Case Reports, 2023 Abstract Type 1 diabetes mellitus (T1DM) with obesity is increasingly common, prompting effective clinical interventions to induce weight loss in this population. We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.
Gunther Wong +2 more
openaire +2 more sources
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Molecules, 2023 Obesity and type 2 diabetes (T2DM) are major public health concerns associated with serious morbidity and increased mortality. Both obesity and T2DM are strongly associated with adiposopathy, a term that describes the pathophysiological changes of the ...
Angelica Artasensi +4 more
doaj +1 more source
Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial [PDF]
, 2012 BACKGROUND: Glucagon like peptide-1 (GLP-1) receptor agonist treatment may improve endothelial function via direct and indirect mechanisms. We compared the acute and chronic effects of the GLP-1 receptor agonist exenatide vs.
Aaron S Kelly +4 more
core +1 more source
Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease [PDF]
, 2015 Recent data have suggested a strong possible link between Type 2 Diabetes Mellitus and Alzheimer’s disease (AD), although exact mechanisms linking the two are still a matter of research and debate. Interestingly, both are diseases with high incidence and
Abuzenadah, Adel M. +8 more
core +1 more source
Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure [PDF]
, 2016 The control of meal size is the best studied aspect of the control of energy balance, and manipulation of this system constitutes a promising target to treat obesity.
Lutz, Thomas A
core +1 more source
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept [PDF]
Molecular MetabolismDaniel A. Briere +17 more
openaire +2 more sources
GLP-1 Agonists in Type 1 Diabetes Mellitus: A Review of the Literature [PDF]
, 2016 Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). Data Sources: A search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the search terms glucagon-like ...
Janzen, Kristin M. +2 more
core +2 more sources